Michael R. Hayden

86.2k citations

817 papers · 59.7k indexed · 10 hit papers · h-index 123

Molecular Biology top 0.02%
Cellular and Molecular Neuroscience top 0.01%
Neurology top 0.01%
Surgery top 0.1%
Genetics top 0.1%

Co-authors: Blair R. Leavitt Cheryl L. Wellington Roshni R. Singaraja Rona K. Graham Liam R. Brunham John J.P. Kastelein Colin J.D. Ross Lynn A. Raymond
Topics: Genetic Neurodegenerative Diseases (403 papers)Mitochondrial Function and Pathology (234 papers)Neurological disorders and treatments (137 papers)
Cited by: Cellular and Molecular Neuroscience Neurology Molecular Biology
Journals: Nature Science New England Journal of Medicine
Partner nations: Canada United States Netherlands

In The Last Decade

Michael R. Hayden

810 papers receiving 58.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Huntington disease

2015 1.1k citations Gillian P. Bates, Michael R. Hayden et al. profile →
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

2001 1.0k citations Blair R. Leavitt, Michael R. Hayden et al. profile →
The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

1993 821 citations Shelin Adam, Michael R. Hayden et al. profile →
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

2002 821 citations Blair R. Leavitt, Michael R. Hayden et al. profile →
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

2003 720 citations Blair R. Leavitt, Michael R. Hayden et al. profile →
A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration

1999 669 citations Blair R. Leavitt, Roshni R. Singaraja et al. profile →
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

1995 633 citations Michael R. Hayden et al. profile →
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length

2004 608 citations Michael R. Hayden et al. profile →
Detection of Huntington's disease decades before diagnosis: the Predict-HD study

2007 605 citations Michael R. Hayden et al. profile →
Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin

2006 505 citations Nagat Bissada, Blair R. Leavitt et al. profile →

Peers

Countries citing papers authored by Michael R. Hayden

Since Specialization

Citations

This map shows the geographic impact of Michael R. Hayden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Hayden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Hayden more than expected).

Fields of papers citing papers by Michael R. Hayden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Hayden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Hayden. The network helps show where Michael R. Hayden may publish in the future.

Co-authorship network of co-authors of Michael R. Hayden

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Hayden. A scholar is included among the top collaborators of Michael R. Hayden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Hayden. Michael R. Hayden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases 2025 ·Pharmaceuticals ·(unknown),Andrew M. Tan,Michal Geva,Andrea Fekete,Carmen Abate,Michael R. Hayden	0
2	Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice 2024 ·Translational Neurodegeneration ·Nicholas S. Caron,Lauren M. Byrne,(unknown),Jeffrey N. Bone,Amirah E.-E. Aly,Seung‐Hyun Ko,Christine Anderson,(unknown),Austin Hill,David J. Hawellek,Peter McColgan,Edward J. Wild,Blair R. Leavitt,Michael R. Hayden	0
3	Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models 2024 ·Brain ·(unknown),Christian Landles,Nicholas S. Caron,(unknown),Georgina F Osborne,Michael R. Hayden,David Howland,Sander van Deventer,Gillian P. Bates,Astrid Vallès,Melvin M. Evers	9
4	Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity 2022 ·Brain Communications ·Nicholas S. Caron,Arsalan S. Haqqani,(unknown),Amirah E.-E. Aly,(unknown),Jeffrey N. Bone,Jodi L. McBride,Abedelnasser Abulrob,Danica Stanimirovic,Blair R. Leavitt,Michael R. Hayden	16
5	Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease 2020 ·Human Molecular Genetics ·Galen E.B. Wright,Nicholas S. Caron,Bernard Ng,(unknown),(unknown),Xiaohong Xu,Jolene Ooi,Mahmoud A. Pouladi,Sara Mostafavi,Colin J.D. Ross,Michael R. Hayden	18
6	Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients 2018 ·Clinical Cancer Research ·Britt I. Drögemöller,Beth Brooks,(unknown),Jose Gerard Monzon,Galen E.B. Wright,Geoffrey Liu,Daniel J. Renouf,Christian Kollmannsberger,Philippe L. Bédard,Michael R. Hayden,Karen A. Gelmon,Bruce Carleton,Colin J.D. Ross	28
7	Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice 2016 ·BMC Biology ·Shaun S. Sanders,Matthew P. Parsons,(unknown),Amber L. Southwell,Sonia Franciosi,(unknown),Sabine Waltl,Lynn A. Raymond,Michael R. Hayden	22
8	More Codeine Fatalities After Tonsillectomy in North American Children 2012 ·PEDIATRICS ·Lauren E. Kelly,Michael Rieder,John van den Anker,(unknown),Colin J.D. Ross,Michael Neely,Bruce Carleton,Michael R. Hayden,Parvaz Madadi,Gideon Koren	273
9	CYP2D6 Polymorphisms and Codeine Analgesia in Postpartum Pain Management: A Pilot Study 2011 ·Therapeutic Drug Monitoring ·(unknown),Howard Berger,Johanna Sistonen,Parvaz Madadi,Ilan Matok,Violette Gijsen,Saskia N. de Wildt,Anna Taddio,Colin J.D. Ross,Bruce Carleton,Michael R. Hayden,Gideon Koren	39
10	Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection 2009 ·Proceedings of the National Academy of Sciences ·Garabet Yeretssian,Karine Doiron,Wei Shao,Blair R. Leavitt,Michael R. Hayden,Donald W. Nicholson,Maya Saleh	48
11	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease 2009 ·Journal of Neuroscience ·Prasad Joshi,(unknown),Véronique M. André,Damian M. Cummings,Carlos Cepeda,John A. Joyce,Jeffrey B. Carroll,Blair R. Leavitt,Michael R. Hayden,Michael S. Levine,Nigel S. Bamford	141
12	Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia 2009 ·Journal of Lipid Research ·Gunilla Olivecrona,Ewa Ehrenborg,Henrik Semb,Elena Makoveichuk,Anna Lindberg,Michael R. Hayden,Peter Gin,Brandon S.J. Davies,Michael M. Weinstein,Loren G. Fong,Anne P. Beigneux,Stephen G. Young,Thomas Olivecrona,Olle Hernell	96
13	Intramuscular Administration of AAV1-Lipoprotein Lipase ^S447X Lowers Triglycerides in Lipoprotein Lipase–Deficient Patients 2008 ·Arteriosclerosis Thrombosis and Vascular Biology ·Erik S.G. Stroes,Melchior C. Nierman,J. J. M. Meulenberg,Remco Franssen,Jaap Twisk,C. P. Henny,Mario Maas,Aeilko H. Zwinderman,Colin J.D. Ross,Eleonora Aronica,Katherine A. High,Marcel M. Levi,Michael R. Hayden,John J.P. Kastelein,Jan Albert Kuivenhoven	145
14	Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus. 2007 ·PubMed ·Michael R. Hayden,(unknown),(unknown),(unknown),Richa Khanna,(unknown)	2
15	Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease 2007 ·Journal of Neuroscience ·Herman B. Fernandes,Kenneth G. Baimbridge,John Church,Michael R. Hayden,Lynn A. Raymond	97
16	Increased ABCA1 activity protects against atherosclerosis 2002 ·Journal of Clinical Investigation ·Roshni R. Singaraja,Catherine Fiévet,Graciela Castro,E. James,Nathalie Hennuyer,Susanne M. Clee,Nagat Bissada,Jonathan C. Choy,Jean‐Charles Fruchart,Bruce M. McManus,Bart Staels,Michael R. Hayden	15
17	Increased ABCA1 activity protects against atherosclerosis 2002 ·Journal of Clinical Investigation ·Roshni R. Singaraja,Catherine Fiévet,Graciela Castro,E. James,Nathalie Hennuyer,Susanne M. Clee,Nagat Bissada,Jonathan C. Choy,Jean‐Charles Fruchart,Bruce M. McManus,Bart Staels,Michael R. Hayden	206
18	Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia 2002 ·Journal of Lipid Research ·Alan Attie,Ronald M. Krauss,Mark P. Gray-Keller,Alison Brownlie,Makoto Miyazaki,John J.P. Kastelein,Aldons J. Lusis,Anton F. H. Stalenhoef,Jonathan P. Stoehr,Michael R. Hayden,James M. Ntambi	309
19	Genetic epidemiology of lipoprotein lipase deficiency in Saguenay-Lac-St-Jean (Québec, Canada). 1992 ·PubMed ·(unknown),C Gagné,Pierre Julien,(unknown),M Lambert,Ghislaine O. Roederer,J. Davignon,Michael R. Hayden,(unknown),(unknown)	5
20	Linkage disequilibrium and modification of risk for Huntington disease. 1991 ·PubMed ·Shelin Adam,Jane Theilmann,Kenneth H. Buetow,A Hedrick,Colin C. Collins,Bernhard H. F. Weber,Marlene J. Huggins,Michael R. Hayden	16

About Michael R. Hayden

Michael R. Hayden is a scholar working on Cellular and Molecular Neuroscience, Neurology and Endocrinology, Diabetes and Metabolism, having authored 817 papers that have together received 59.7k indexed citations. Recurring topics across this work include Genetic Neurodegenerative Diseases (403 papers), Mitochondrial Function and Pathology (234 papers) and Neurological disorders and treatments (137 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (29.3k citations), Neurology (12.7k citations) and Molecular Biology (35.7k citations). Michael R. Hayden has collaborated with scholars based in Canada, United States and Netherlands. Frequent co-authors include Blair R. Leavitt, Cheryl L. Wellington, Roshni R. Singaraja, Rona K. Graham, Liam R. Brunham, John J.P. Kastelein, Colin J.D. Ross, Lynn A. Raymond, Y. Paul Goldberg and Mahmoud A. Pouladi. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact